酪酸梭菌活菌片对乙肝免疫球蛋白水平影响
The Effect of Clostridium butyricum Viable Tablet on the Level of Hepatitis B Immunoglobulin
摘要: 目的：探讨酪酸梭菌活菌片对慢性乙型病毒性肝炎患者肝功能及免疫球蛋白(IgG、IgA、IgM)的影响。方法：收集2018年1月至2019年12月于我院肝炎门诊就诊的慢性乙型肝炎患者40名，采用全自动生化分析仪检测患者治疗前后的肝功能及IgG、IgA、IgM的变化，探讨酪酸梭菌活菌片与慢性乙型病毒性肝炎患者肝功能及IgG、IgA、IgM水平的相关性。结果：酪酸梭菌活菌片对慢性乙型病毒性肝炎患者肝功能及IgG、IgA、IgM水平有显著影响，观察组患者免疫球蛋白指标高于对照组健康成年人，两组间差异存在统计学意义(P < 0.05)；观察组患者治疗前后的免疫球蛋白指标前下降，差异有统计学意义(P < 0.05)。结论：口服酪酸梭菌活菌片可作为治疗慢性HBV感染的新策略。
Abstract: Objective: To investigate the effect of Clostridium butyricum viable tablet on liver function, IgG, IgA and IgM in patients with chronic hepatitis B. Methods: We collected 40 patients with chronic hepatitis B who visited the hepatitis clinic in our hospital from January 2018 to December 2019. The liver function and the changes of IgG, IgA and IgM before and after treatment were detected by automatic biochemical analyzer. To explore the correlation between Clostridium butyricum viable tablet and liver function and IgG, IgA and IgM levels in patients with chronic hepatitis B. Results: The Clostridium butyricum viable tablet has significant effect on liver function and the levels of IgG, IgA and IgM in patients with chronic hepatitis B. The immunoglobulin index in the observation group was higher than that in the control group. The difference between the two groups was statistically significant (P < 0.05); the immunoglobulin index of the observation group decreased before and after treatment. The difference between the two groups was statistically significant (P < 0.05). Conclusions: Oral Clostridium butyricum viable tablet can be used as a new strategy for the treatment of chronic HBV infection.
文章引用：张红云, 陆景锋, 张来海, 李艳艳, 田怡, 张曹庚, 倪菊平, 徐瑞芳. 酪酸梭菌活菌片对乙肝免疫球蛋白水平影响[J]. 临床医学进展, 2021, 11(3): 925-929. https://doi.org/10.12677/ACM.2021.113133

参考文献

[1] 江泳, 关玉龙, 韩小玲, 等. 酪酸梭菌活菌片散联合水飞蓟宾胶囊治疗非酒精性脂肪性肝病患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(15): 2212-2215.
[2] 徐莹莹, 龚建玲, 严亚丹, 等. 慢性乙型肝炎病毒感染者血清脂联素水平与体液免疫功能的相关性研究[J]. 现代实用医学, 2016, 28(5): 592-594.
[3] 张云云, 张琳, 刘洁, 等. 免疫球蛋白检验在慢性乙型肝炎患者中的应用价值[J]. 临床医学研究与实践, 2020, 5(19): 95-96+99.
[4] 王贵强, 王福生, 庄辉, 等. 慢性乙型肝炎防治指南(2019年版) [J]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 441-466.
[5] 张利娥, 李娜, 等. 双歧杆菌乳杆菌三联活菌片对肝硬化自发性腹膜炎患者血清CRP、IL-2的影响[J]. 现代消化及介入诊疗, 2018, 23(4): 483-485.
[6] 梁丹红, 黄换桂, 郭凤媚, 等. 不同自身免疫性肝病患者肝功能及IgG、IgA、IgMG4水平差异分析[J]. 中国医学工程, 2016, 24(7): 79-80.
[7] 徐莹莹, 龚建玲, 严亚丹, 等. 慢性乙型肝炎病毒感染者血清脂联素水平与体液免疫功能的相关性研究[J]. 现代实用医学, 2016, 28(5): 592-594.
[8] 杨晓婷, 赖广华, 卓李圆, 等. 血清甲状腺激素、免疫球蛋白的表达与慢性乙型肝炎的相关性研究[J]. 中国病案, 2018, 19(9): 99-101.
[9] 许庆, 徐元宏. 慢性肝病患者血小板与血清IgG水平变化及意义[J]. 山东医药, 2016, 56(37): 96-98.
[10] 陈益泉, 等. 浅谈对慢性乙肝所致肝衰竭患者进行血清IgG、IgM及IgA检测的意义[J]. 当代医药论丛, 2016, 14(19): 87-88.
[11] 徐莹莹, 龚建玲, 严亚丹, 等. 慢性乙型肝炎病毒感染者血清脂联素水平与体液免疫功能的相关性研究[J]. 现代实用医学, 2016, 28(5): 592-594.
[12] 李雷花等. 肝功能及IgG、IgA、IgMIgG和IgM及IgA水平的检测对慢性乙肝肝衰竭的诊断价值[J]. 内蒙古医学杂志, 2019, 51(10): 1226-1227.
[13] 中华预防医学会微生态学分会. 中国微生态调节剂临床应用专家共识(2020版) [J]. 中国微生态学杂志, 2020, 32(8): 953-965.

为你推荐